Gene-nutrient interactions in G6PD-deficient subjects - Implications for cardiovascular disease susceptibility

Journal of Nutrigenetics and Nutrigenomics

Volumn 1, Issue 1-2, 2007, Pages 49-54

  Muntoni, Sergio ^a,b   Muntoni, Sandro ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b MEDICO Association   (Italy)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase; Cardiovascular diseases; Cholesterogenesis; Favism; Gene nutrient interactions; Glucose 6 phosphate dehydrogenase; Wine consumption

Indexed keywords

ASCORBIC ACID; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; PRASTERONE SULFATE; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DNA SYNTHESIS; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH SURVEY; HUMAN; MONONUCLEAR CELL; MORTALITY; NUTRIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SHORT SURVEY;

CARDIOVASCULAR DISEASES; DIET; FOOD; GENETIC PREDISPOSITION TO DISEASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; OXIDATION-REDUCTION;

VICIA FABA;

EID: 35648956629     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000109874     Document Type: Short Survey

References (40)

1. Luzzatto L, Mehta A, Vulliamy T: Glucose 6-phosphate dehydrogenase deficiency; in Scriver CR, Beaudet AL, Sly WS (eds): The Metabolic Basis of Inherited Diseases, ed 8. New York, McGraw Hill, 2001, pp 4517-4553.
2. Luzzatto L: Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. Haematologica 2006;91:1303-1306.
3. Beutler E: Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 1991;324:169-174.
4. Hanukoglu I, Rapaport R: Routes and regulation of NADPH production in steroidogenic mitochondria. Endocr Res 1995;21:231-241.
5. Sanna E, Bruno R, Cosseddu GG, Floris G, Salis A, Silvetti M: Present-day G-6-PD deficit in Sardinia with respect to malarial morbidity and mortality in the past. Z Morph Anthrop 1990;78:257-267.
6. Luzzatto L, Usanga EA, Reddy S: Glucose 6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites. Science 1969;164:839-842.
7. Muntoni S, Pintus F, Mascia P, Pintus P, Podda E, Cabiddu GF, Tronci P, Ganga E, Contini PP, Congiu P, Trudu A, Baule GM, Sanna A, Onorato D, Mereu P, Seccareccia F, Conti S, Menotti A: The effects of wine consumption on plasma cholesterol levels are blunted in men deficient in glucose 6-phosphate dehydrogenase. Proc IX Int Symp DALM, Florence, 1986, abstr, p 150.
8. Chan TK, Todd W, Wong CC: Tissue enzyme levels in erythrocyte glucose 6-phosphate dehydrogenase deficiency. J Lab Clin Med 1965;66:937-942.
9. -) is expressed in the liver. J Lab Clin Med 1979;93:783-789.
10. Battistuzzi G, D'Urso M, Toniolo D, Persico GM, Luzzatto L: Tissue-specific levels of human glucose 6-phosphate dehydrogenase correlate with methylation of specific sites at the 3′ end of the gene. Proc Natl Acad Sci USA 1985;82:1465-1469.
11. Long WK, Wilson SW, Frenkel EP: Association between red cell glucose 6-phosphate variants and vascular disease. Am J Hum Genet 1967;19:35-53.
12. Muntoni S, Pintus F, Mascia P, Pintus P, Ganga E, Menotti A: Lipidi plasmatici nella condizione di carenza di glucosio-6-fosfato deidrogenasi. Giorn Arterioscl 1989;14:123-129.
13. Blackburn H: The potential for prevention of atherosclerosis in children. Ann NY Acad Sci 1991;623:2-8.
14. Cocco P, Todde P, Fornera S, Manca MB, Manca P, Sias AR: Mortality in a cohort of men expressing the glucose 6-phosphate dehydrogenase deficiency. Blood 1998;91:706-709.
15. Muntoni Sa, Manca MR, Cocco PL, Meloni L, Muntoni S: Glucose 6-phosphate dehydrogenase deficiency and coronary heart disease (abstract). Nutr Metab Cardiovasc Dis 2004;14:299.
16. Muntoni S, Muntoni Sa: Genetic influences on serum LDL levels and type 1 diabetes incidence in Sardinia; in Simopulos AP, Pavlou KN (eds): Nutrition and Fitness: Diet, Genes, Physical Activity and Health. Basel, Karger, 2001, vol 89, pp 76-82.
17. Siperstein MD: Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 1984;25:1462-1468.
18. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990;343:425-430.
19. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-1164.
20. Quesney-Huneeus V, Wiley MH, Siperstein MD: Isopentenyladenine as a mediator of mevalonate-regulated DNA replication. Proc Natl Acad Sci USA 1980;77:5842-5846.
21. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A: Non-lipid-related effects of statins. Ann Med 2000;32:164-176.
22. Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A: Clinically relevant pleiotropic effects of statins: drug properties on effect of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001;11:328-343.
23. Marks PH, Banks J: Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroids. Proc Natl Acad Sci USA 1960;46:447-452.
24. Muntoni S: G-6-PD deficiency: a naturally-occurring model of HMG-CoA reductase restraint. Ann Nutr Metab 2003;47:229-254.
25. Lopez SA, Wingo C, Hebert JA: Total serum cholesterol and urinary dehydroepiandrosterone in humans. Atherosclerosis 1976;24:471-481.
26. Scandinavian Simvastatin Survival Study (4S): Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
27. Barrett-Connor E, Khaw K-F, Yen SSC: A prospective study of dehydroepiandrosterone sulphate, mortality and cardiovascular disease. N Engl J Med 1986;315:1519-1524.
28. Heart Protection Study Collaborative Group: Effect of cholesterol lowering with simvastatin on stroke and other major cardiovascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
29. Lapchak PA, Chapman D, Nunez SY, Zivian JA: Dehydroepiandrosterone is neuroprotective in a reversible spinal cord ischemia model. Stroke 2003;31:1953-1957.
30. Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J: Glucose 6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J 2001;15:1771-1773.
31. Leopold JA, Loscalzo J: Oxidative enzymophaties and vascular disease. Arterioscl Thromb Vasc Biol 2005;25:1332-1340.
32. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003;52:1-8.
33. Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The Common Soil hypothesis revisited. Arterioscl Thromb Vasc Biol 2004;24:816-823.
34. Loscalzo J: Oxidant stress: A key determinant of atherothrombosis. Biochem Soc Trans 2003;31:1059-1061.
35. Matsui R, Xu S, Maitland KA, Hayes A, Leopold JA, Handy DE, Loscalzo J, Cohen RA: Glucose-6 phosphate dehydrogenase deficiency decreases the vascular response to angiotensin II. Circulation 2005;112:257-263.
36. Matsui R, Xu S, Maitland KA, Mastroianni R, Leopold JA, Handy DE, Loscalzo J, Cohen RA: Glucose-6 phosphate dehydrogenase deficiency decreases vascular superoxide and atherosclerotic lesions in apolipoprotein E-/- Mice. Arterioscler Thromb Vasc Biol 2006;26:910-916.
37. Zalba G, Beloqui O, San José G, Moreno MU, Fortuño A, Dìez J: NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005;25:1452-1457.
38. Park J, Choe SS, Choi AH, Kim KH, Yoon MJ, Suganami T, Ogawa Y, Kim JB: Increase in glucose-6-phosphate dehydrogenase in adipocytes stimulates oxidative stress and inflammatory signals. Diabetes 2006;55:2939-2949.
39. Park J, Rho HK, Kim KH, Choe SS, Lee YS, Kim JB: Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol Cell Biol 2005;25:5146-5157.
40. Endres M: Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006;7:31-35.